PE122299A1 - Metodo para reducir las ansias de consumo en mamiferos - Google Patents

Metodo para reducir las ansias de consumo en mamiferos

Info

Publication number: PE122299A1
Authority: PE; Peru
Prior art keywords: agonists; cocaine; anxiety; peptios; reduce
Prior art date: 1997-10-28

Application number

PE1998001010A

Other languages

English (en)

Spanish (es)

Inventor

Vicki Coffin

Paul W Glue

Original Assignee

Schering Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-10-28

Filing date

1998-10-27

Publication date

1999-12-04

1998-10-27 Application filed by Schering Corp filed Critical Schering Corp

1999-12-04 Publication of PE122299A1 publication Critical patent/PE122299A1/es

Links

208000019901 Anxiety disease Diseases 0.000 title abstract 2
230000036506 anxiety Effects 0.000 title abstract 2
241000124008 Mammalia Species 0.000 title 1
ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 abstract 6
239000000556 agonist Substances 0.000 abstract 4
239000005557 antagonist Substances 0.000 abstract 3
229960003920 cocaine Drugs 0.000 abstract 3
229940079593 drug Drugs 0.000 abstract 2
239000003814 drug Substances 0.000 abstract 2
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 abstract 2
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 abstract 1
KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 abstract 1
108091032151 5-hydroxytryptamine receptor family Proteins 0.000 abstract 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
102000014630 G protein-coupled serotonin receptor activity proteins Human genes 0.000 abstract 1
102000051325 Glucagon Human genes 0.000 abstract 1
108060003199 Glucagon Proteins 0.000 abstract 1
229940127470 Lipase Inhibitors Drugs 0.000 abstract 1
241000208125 Nicotiana Species 0.000 abstract 1
235000002637 Nicotiana tabacum Nutrition 0.000 abstract 1
229940025084 amphetamine Drugs 0.000 abstract 1
230000003579 anti-obesity Effects 0.000 abstract 1
239000000935 antidepressant agent Substances 0.000 abstract 1
229940005513 antidepressants Drugs 0.000 abstract 1
239000000164 antipsychotic agent Substances 0.000 abstract 1
229940005529 antipsychotics Drugs 0.000 abstract 1
XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 abstract 1
230000003197 catalytic effect Effects 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
229940052760 dopamine agonists Drugs 0.000 abstract 1
239000003136 dopamine receptor stimulating agent Substances 0.000 abstract 1
235000012631 food intake Nutrition 0.000 abstract 1
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 abstract 1
229960004666 glucagon Drugs 0.000 abstract 1
229960002715 nicotine Drugs 0.000 abstract 1
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 abstract 1
229940127240 opiate Drugs 0.000 abstract 1
229940076279 serotonin Drugs 0.000 abstract 1
UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 abstract 1
229960004425 sibutramine Drugs 0.000 abstract 1
239000000021 stimulant Substances 0.000 abstract 1
239000000126 substance Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Neurosurgery (AREA)
Addiction (AREA)
Child & Adolescent Psychology (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

PE1998001010A 1997-10-28 1998-10-27 Metodo para reducir las ansias de consumo en mamiferos PE122299A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US95921397A	1997-10-28	1997-10-28

Publications (1)

Publication Number	Publication Date
PE122299A1 true PE122299A1 (es)	1999-12-04

Family

ID=25501785

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PE1998001010A PE122299A1 (es)	1997-10-28	1998-10-27	Metodo para reducir las ansias de consumo en mamiferos

Country Status (16)

Country	Link
EP (1)	EP1043980A2 (fr)
JP (1)	JP2001520989A (fr)
KR (1)	KR20010031470A (fr)
CN (1)	CN1283116A (fr)
AR (1)	AR015984A1 (fr)
AU (1)	AU1110099A (fr)
BR (1)	BR9814830A (fr)
CA (1)	CA2308453A1 (fr)
CO (1)	CO4970824A1 (fr)
HU (1)	HUP0100115A2 (fr)
IL (1)	IL135659A0 (fr)
NO (1)	NO20002149L (fr)
PE (1)	PE122299A1 (fr)
SK (1)	SK5812000A3 (fr)
WO (1)	WO1999021540A2 (fr)
ZA (1)	ZA989786B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BR9908392A (pt) *	1998-03-02	2000-10-31	Schering Corp	Uso de antagonistas de d1/d5 para o tratamento de distúrbios obsessivos compulsivos, distúrbios somatofórmicos, distúrbios dissociativos, distúrbios de alimentação, distúrbios de controle de impulsos e autismo
US6410527B1 (en) *	1998-03-02	2002-06-25	Schering Corporation	Method of treating obsessive compulsive disorders, somatoform disorders, dissociative disorders, eating disorders, impulse control disorders, and autism
US6541520B1 (en)	1998-08-05	2003-04-01	Brookhaven Science Associates	Treatment of addiction and addiction-related behavior
US6890951B2 (en)	1998-08-05	2005-05-10	Brookhaven Science Associates Llc	Treatment of addiction and addiction-related behavior
IL137937A0 (en) *	1999-08-27	2001-10-31	Pfizer Prod Inc	A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
US6395783B1 (en)	2000-10-23	2002-05-28	Brookhaven Science Associates, Llc	Treatment of PCP addiction and PCP addiction-related behavior
US6462084B1 (en)	2001-05-14	2002-10-08	Brookhaven Science Associates, Llc	Treatment for obsessive-compulsive disorder (OCD) and OCD-related disorders using GVG
EP1441708B1 (fr)	2001-11-05	2009-04-08	Krele Pharmaceuticals LLC	Compositions et methodes permettant d'augmenter l'observance therapeutique au moyen d'inhibiteurs de l'aldehyde deshydrogenase et traitement de l'alcoolisme
WO2012050594A1 (fr)	2010-09-01	2012-04-19	Tonix Pharmaceuticals, Inc.	Traitement contre la cocaïnomanie
PL2872145T3 (pl)	2012-07-12	2022-06-20	Emalex Biosciences, Inc.	Połączone benzazepiny w leczeniu zespołu tourette’a
LT3057595T (lt)	2013-10-18	2020-08-10	Emalex Biosciences, Inc.	Sintezuoti benzazepinai, skirti mikčiojimui gydyti
CN110327350B (zh) *	2019-07-11	2021-02-23	温州医科大学	多巴胺d1受体拮抗剂sch39166在作为制备治疗眼部病理性血管新生药物的应用
CN110833621A (zh) *	2019-12-06	2020-02-25	中国医科大学	多巴胺受体1拮抗剂在制备治疗对氯胺酮致小鼠类精神分裂症药物上的应用
US12594281B2 (en)	2024-03-15	2026-04-07	Emalex Biosciences, Inc.	Pharmaceutical dosage forms and methods of use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5607967A (en) *	1994-10-27	1997-03-04	Merck & Co., Inc.	Treatment of alzheimer's disease with 5-(tetradecyloxy)-2-furan carboxylic acid
AU3408097A (en) *	1996-06-06	1998-01-05	Ergo Research Corporation	Treatment of lipid and glucose metabolism disorders with dopamine and seroto nin agonists

1998
- 1998-10-26 KR KR1020007004505A patent/KR20010031470A/ko not_active Withdrawn
- 1998-10-26 HU HU0100115A patent/HUP0100115A2/hu unknown
- 1998-10-26 AU AU11100/99A patent/AU1110099A/en not_active Abandoned
- 1998-10-26 CN CN98812730A patent/CN1283116A/zh active Pending
- 1998-10-26 CO CO98062495A patent/CO4970824A1/es unknown
- 1998-10-26 BR BR9814830-3A patent/BR9814830A/pt not_active Application Discontinuation
- 1998-10-26 EP EP98953826A patent/EP1043980A2/fr not_active Withdrawn
- 1998-10-26 IL IL13565998A patent/IL135659A0/xx unknown
- 1998-10-26 WO PCT/US1998/022255 patent/WO1999021540A2/fr not_active Ceased
- 1998-10-26 CA CA002308453A patent/CA2308453A1/fr not_active Abandoned
- 1998-10-26 SK SK581-2000A patent/SK5812000A3/sk unknown
- 1998-10-26 JP JP2000517699A patent/JP2001520989A/ja not_active Withdrawn
- 1998-10-27 PE PE1998001010A patent/PE122299A1/es not_active Application Discontinuation
- 1998-10-27 ZA ZA989786A patent/ZA989786B/xx unknown
- 1998-10-27 AR ARP980105373A patent/AR015984A1/es unknown
2000
- 2000-04-27 NO NO20002149A patent/NO20002149L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
SK5812000A3 (en)	2000-12-11
JP2001520989A (ja)	2001-11-06
CO4970824A1 (es)	2000-11-07
CA2308453A1 (fr)	1999-05-06
WO1999021540A3 (fr)	1999-09-02
IL135659A0 (en)	2001-05-20
WO1999021540B1 (fr)	1999-10-28
EP1043980A2 (fr)	2000-10-18
NO20002149D0 (no)	2000-04-27
AU1110099A (en)	1999-05-17
CN1283116A (zh)	2001-02-07
HUP0100115A2 (hu)	2001-06-28
ZA989786B (en)	1999-04-28
KR20010031470A (ko)	2001-04-16
AR015984A1 (es)	2001-05-30
NO20002149L (no)	2000-06-26
BR9814830A (pt)	2000-10-03
WO1999021540A2 (fr)	1999-05-06

Similar Documents

Publication	Publication Date	Title
PE122299A1 (es)	1999-12-04	Metodo para reducir las ansias de consumo en mamiferos
AR029605A1 (es)	2003-07-10	DERIVADOS DE DIFENILUREA SUBSTITUIDOS CON SULFONAMIDA , COMPOSICIoN FARMACEUTICA , USO DE LOS MISMOS PARA LA MANUFACTURA DE UN MEDICAMENTO uTILES COMO ANTAGONISTA DE RECEPTORES DE IL-8, COMPUESTOS, INTERMEDIARIOS, Y MÉTODOS DE CONVERSIoN DE COMPUESTOS
Popik et al.	1999	Pharmacology of ibogaine and ibogaine-related alkaloids
EA200300183A1 (ru)	2003-08-28	Новое сочетание агониста (5-th2) и антагониста (5-ht6) серотонина в качестве фармацевтической композиции
Waldeck	2003	Three‐dimensional pharmacology, a subject ranging from ignorance to overstatements
PT1218352E (pt)	2004-09-30	Novos derivados de benzimidazolona tendo receptores com afinidade mista para os receptores de serotonina e dopamina
CO5011096A1 (es)	2001-02-28	Medicamentos que contienen antagonistas del receptor 5-ht3 para el tratamiento de la ibs
Anand et al.	1994	Neuroendocrine and behavioral responses to intravenous m-chlorophenylpiperazine (mCPP) in depressed patients and healthy comparison subjects.
ES2060191T3 (es)	1994-11-16	Medios para el uso como ayuda para dejar de fumar o para el uso en zonas en las que no esta permitido fumar.
EA200100058A1 (ru)	2001-08-27	4-бензилпиперидиналкилсульфоксидные гетероциклические соединения и их применение в качестве подтип-избирательных антагонистов nmda-рецепторов
AR028505A1 (es)	2003-05-14	Utilizacion de un antagonista de los receptores de cannabinoides centrales para la preparacion de medicamentos utiles para que sea mas frcil detener el consumo de tabaco
AR006545A1 (es)	1999-09-08	Compuestos sustitutos de las catecolaminas, utiles como antagonistas beta3, composiciones farmaceuticas que los contienen y compuestos intermediarios deaplicacion exclusiva en la preparacion de dichos compuestos
AR020442A1 (es)	2002-05-15	Agonistas de 5ht2serotonergicos para el tratamiento de glaucoma
CA2305799A1 (fr)	1999-04-15	Composition de traitement de la dependance a la nicotine contenant un antagoniste du recepteur a la nicotine et medicament antidepresseur ou anxiolytique
ECSP045517A (es)	2005-03-10	Procedimiento para dejar de fumar
DK1019426T3 (da)	2003-07-14	Hidtil ukendte A1-adenosinreceptoragonister og -antagonister
Dortch‐Carnes et al.	2005	Bremazocine: A κ‐Opioid Agonist with Potent Analgesic and Other Pharmacologic Properties
BRPI0316895B8 (pt)	2019-09-03	composto, processo para a preparação do composto, composição farmacêutica e uso do composto
AR022970A1 (es)	2002-09-04	Compuestos antagonistas de la lhrh con propiedades mejoradas de sulubilidad, procedimiento para prepararlos, las composiciones farmrceuticas que los contienen, su uso para la preparacinn de medicamentos, y procedimiento para preparar dichos medicamentos
PE20010577A1 (es)	2001-05-08	Composicion farmaceutica para la prevencion y tratamiento de la adiccion a la nicotina que comprende un agonista del receptor nicotinico, un agente antidepresivo o ansiolitico
Ferrari et al.	1994	The selective D2 dopamine receptor antagonist eticlopride counteracts the ejaculatio praecox induced by the selective D2 dopamine agonist SND 919 in the rat
IT1313585B1 (it)	2002-09-09	Uso di agonisti dei recettori gabab per la terapia di mantenimentodell'astinenza da nicotina in soggetti nicotino-dipendenti.
Dekeyne et al.	2003	Discriminative stimulus properties of antidepressant agents: a review
EA200100540A1 (ru)	2001-10-22	Фармацевтическая композиция с модифицированным высвобождением сенсибилизатора к инсулину
CO5200833A1 (es)	2002-09-27	Regimenes de dosificacion para lasofoxifeno

Legal Events

Date	Code	Title	Description
2001-08-28	FC	Refusal